India CAR-T therapy development has a new manufacturing partnership: Nucelion Therapeutics, a wholly owned subsidiary of Bharat Biotech, and Hyderabad-based VeGen Bio announced on 21 October 2026 that they will work together on VL-2511, an experimental dual-target BCMA/CD19 CAR-T cell therapy for multiple myeloma. Nucelion will provide technology transfer, process development and manufacturing, and the companies plan to advance the therapy towards Phase 1/2 trials in India, with 2028 named as a commercialisation target subject to regulatory approvals. VL-2511 is not an approved treatment. This report explains what the partnership covers, what it does not, and what to watch. It is general information and not medical advice.
India CAR-T therapy development: key takeaways
- Nucelion will act as technology transfer partner and as clinical- and commercial-stage manufacturing partner for VL-2511, according to the reports.
- VL-2511 is an experimental autologous CAR-T therapy that targets both BCMA and CD19 and is being developed for multiple myeloma.
- The companies plan Phase 1/2 trials in India and identify 2028 as a commercialisation target, subject to clinical progress and approvals; it is not a confirmed launch date.
- The deal is for manufacturing and development, not for marketing or distribution.
- No financial terms, patient numbers or trial dates were given in the reports we reviewed.
What the India CAR-T therapy development partnership covers
According to published reports, Nucelion will provide technology transfer, process development and manufacturing for VL-2511, from making trial material to, eventually, supporting commercial production. VeGen Bio brings the therapy and its scientific expertise. The reports say the framework is meant to host other VeGen Bio cell therapy candidates later and that the partners will work on yields and operational efficiency to lower production costs and improve access in India. One report says marketing and distribution are explicitly excluded.
VL-2511 and India CAR-T therapy development: the dual-target design
General background: CAR-T therapy takes a patient’s own T cells, engineers them to carry a receptor that recognises a protein on cancer cells and returns them to the patient. BCMA is a protein found on myeloma cells, and CD19 is found on certain other B-cell lineage cells. The companies say that aiming at two proteins at once may reduce the chance that cancer cells escape treatment by losing one target. That is the company’s reasoning and not a demonstrated result, and the reports we reviewed give no clinical data for VL-2511 in India.
What is known about the clinical history
One report says VL-2511 has undergone clinical development in China and is also being developed in the United States. Another describes it as a first-in-class dual BCMA/CD19 autologous therapy that is also under clinical investigation for POEMS syndrome and selected autoimmune disorders, including lupus. These are company descriptions. We found no published trial results in the sources we reviewed, so we cannot assess safety or effectiveness. The planned Indian study is described as a Phase 1/2 trial, which is an early stage designed mainly to study safety and dosing.
Why India CAR-T therapy development depends on manufacturing
This section is our analysis. CAR-T products are made for each patient, which means the manufacturing process, facility and quality systems are as central to success as the science. High production cost and specialised infrastructure are widely cited barriers to access in India, and one report says the partners aim to lower cost through efficiency. India already has an indigenous CAR-T treatment, NexCAR19, developed by ImmunoACT with IIT Bombay and Tata Memorial Centre, according to one report. A second domestic developer and a dedicated manufacturer would widen the base, but the outcome depends on trial results.
Nucelion and its facility
The reports describe Nucelion as a cell and gene therapy contract research, development and manufacturing organisation, or CRDMO, and as one of India’s first dedicated ones. One report says it will use its manufacturing facility in Hyderabad and that the site is designed to meet CDSCO, US FDA and EMA standards. The other report does not give a location. Nucelion’s other reported partnerships include Pandorum Technologies on regenerative eye therapies, the Nordic Cell Therapy Group and Quantoom Biosciences. More is on the Nucelion website.
What the 2028 target means for India CAR-T therapy development
The companies identify 2028 as a commercialisation target, subject to clinical progress and regulatory approvals. A target is an aim, not a commitment. Any Indian approval would require trial data and a review by the Central Drugs Standard Control Organisation, and trials in India are normally registered with the Clinical Trials Registry of India. Early-stage programmes often change timelines as data arrive, so readers should not treat 2028 as a launch date.
What is not disclosed about India CAR-T therapy development
- Financial terms of the agreement.
- Trial design, number of patients, sites and start date.
- Clinical results for VL-2511 from the earlier studies.
- Expected price or the number of patients who could be treated.
Risks and caveats on India CAR-T therapy development
- VL-2511 is experimental and unapproved; no efficacy or safety claims can be made.
- Manufacturing partnerships do not guarantee clinical success.
- Company statements have not been independently verified.
- This is news reporting, not medical advice.
In our assessment, this partnership is a manufacturing milestone for India CAR-T therapy development, but its real test is whether VL-2511 shows safe and durable responses in Indian patients and whether production can scale at a lower cost. See also Mankind Pharma CAR-T Acquisition: Bold €48M Cancer Bet. More in our biotechnology coverage.
What to watch next on India CAR-T therapy development
- Trial registration and the start of the Phase 1/2 study.
- Early safety and response data for VL-2511.
- Further partnerships under the Nucelion framework.
Frequently asked questions
What is VL-2511?
An experimental dual-target BCMA/CD19 CAR-T cell therapy for multiple myeloma, developed by VeGen Bio.
What will Nucelion do?
Provide technology transfer, process development and manufacturing for clinical and, if approved, commercial supply.
Is VL-2511 available in India?
No. It is experimental; the companies plan Phase 1/2 trials and name 2028 as a commercialisation target subject to approvals.
How we reported this: we relied on published reports of the 21 October 2026 announcement and the company website, and we did not see trial data or the agreement itself. Company claims and our analysis are labelled. Last updated: 23 October 2026. This article is news reporting and not medical advice.
[…] According to the announcement as reported, Pandorum develops cell-free regenerative medicines whose biological activity is tuned to address inflammation, fibrosis and vascular problems while supporting tissue repair. Nucelion will handle process development and manufacturing matched to each programme’s requirements and development stage. The broader aim is to supply GMP-manufactured material for clinical studies in India and abroad, subject to regulatory approvals. Nucelion’s parent group is described at bharatbiotech.com. Our earlier report on Nucelion’s other collaboration is India CAR-T Therapy Development: Nucelion, VeGen Bio Pact. […]